Haemonetics Corporation (NYSE:HAE) – Analysts at Jefferies Group lowered their FY2022 EPS estimates for Haemonetics Corporation in a note issued to investors on Friday. Jefferies Group analyst A. Petrone now anticipates that the medical instruments supplier will post earnings per share of $3.22 for the year, down from their prior estimate of $3.52. Jefferies Group currently has a “Buy” rating and a $48.00 target price on the stock.

A number of other analysts have also recently commented on the company. BidaskClub cut Haemonetics Corporation from a “hold” rating to a “sell” rating in a research report on Friday, June 23rd. Zacks Investment Research cut Haemonetics Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. TheStreet cut Haemonetics Corporation from a “b-” rating to a “c” rating in a research report on Monday, May 8th. JMP Securities raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a research report on Thursday, July 13th. Finally, Barrington Research raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price target on the stock in a research report on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $40.71.

TRADEMARK VIOLATION WARNING: “Jefferies Group Research Analysts Reduce Earnings Estimates for Haemonetics Corporation (HAE)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/jefferies-group-research-analysts-reduce-earnings-estimates-for-haemonetics-corporation-hae/1528144.html.

Shares of Haemonetics Corporation (NYSE:HAE) traded up 0.63% during midday trading on Monday, reaching $41.76. The company had a trading volume of 16,799 shares. The stock’s 50 day moving average is $40.94 and its 200-day moving average is $40.32. Haemonetics Corporation has a 12-month low of $32.76 and a 12-month high of $43.74. The stock has a market capitalization of $2.20 billion, a PE ratio of 542.34 and a beta of 0.90.

Haemonetics Corporation (NYSE:HAE) last announced its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The business had revenue of $211 million for the quarter, compared to analyst estimates of $211.29 million. During the same quarter last year, the firm earned $0.25 EPS. Haemonetics Corporation’s revenue for the quarter was up .5% compared to the same quarter last year.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Haemonetics Corporation by 48,854.9% in the first quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock worth $255,175,000 after buying an additional 6,276,880 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Haemonetics Corporation by 22.6% in the first quarter. Wellington Management Group LLP now owns 4,192,350 shares of the medical instruments supplier’s stock worth $170,084,000 after buying an additional 774,089 shares in the last quarter. Columbia Wanger Asset Management LLC bought a new stake in shares of Haemonetics Corporation during the first quarter worth approximately $23,786,000. Vanguard Group Inc. boosted its stake in shares of Haemonetics Corporation by 7.6% in the first quarter. Vanguard Group Inc. now owns 4,694,325 shares of the medical instruments supplier’s stock worth $190,449,000 after buying an additional 332,087 shares in the last quarter. Finally, Black Creek Investment Management Inc. raised its position in shares of Haemonetics Corporation by 24.8% in the first quarter. Black Creek Investment Management Inc. now owns 1,396,483 shares of the medical instruments supplier’s stock worth $56,655,000 after buying an additional 277,870 shares during the last quarter.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Earnings History and Estimates for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.